Fenbendazole in Chemo-Refractory Cancers
Three patients with various genitourinary malignancies who demonstrated complete response after receiving fenbendazole therapy as a single or supplementary chemotherapeutic agent. In two patient scenarios, they had experienced progression of metastatic disease despite multiple lines of therapy prior to initiation of fenbendazole. No fenbendazole-related side effects were reported.
The paper highlights a Stanford University case series evaluating fenbendazole, which destabilizes microtubules through a mechanism similar to anti-oncogenic vinca alkaloids:
Overcoming Multi-Line Chemotherapy Failure:
Case 1 (Renal Cell Carcinoma): A 63-year-old man with metastatic stage 4 clear cell renal cell carcinoma failed three consecutive lines of therapy (pazopanib, cabozantinib, and nivolumab). After starting 1,000 mg of fenbendazole three times weekly, follow-up MRI showed near-complete resolution of the primary renal mass and decreased pancreatic and bone metastases.
Case 2 (Urothelial Carcinoma): A 72-year-old man with metastatic urothelial carcinoma experienced disease progression after failing radiotherapy, carboplatin, paclitaxel, pembrolizumab, and six cycles of gemcitabine plus cisplatin. After starting 1,000 mg fenbendazole three days per week (alongside Vitamin E, Curcumin, and CBD oil), follow-up CT scans showed a complete radiographic response, with complete disappearance of his aortocaval lymph node metastasis.
Concurrent Chemotherapy Combination:
Case 3 (Bladder Cancer): A 63-year-old woman with advanced urothelial bladder carcinoma was treated with 6 cycles of AMVAC chemotherapy (accelerated methotrexate, vinblastine, doxorubicin, and cisplatin) concurrently with 1 gram of fenbendazole three times weekly. Follow-up CT revealed no evidence of disease.
Source:
Citation: Chiang RS, Syed AB, Wright JL, Montgomery B, Srinivas S (2021) Fenbendazole Enhancing Anti-Tumor Effect: A Case Series. Clin Oncol Case Rep 4:2
Fenbendazole Enhancing Anti-Tumor Effect: A Case Series
Ryan S Chiang, Ali B Syed, Jonathan L Wright, Bruce Montgomery and Sandy Srinivas
Chiang et al.
Case Report, Clin Oncol Case Rep Vol: 4 Issue: 2
*Corresponding author: Ryan Chiang, Department of Medicine, Stanford University Medical Center, Stanford, 410 Station Park Circle Unit 107, San Mateo, CA 94402, CA, USA, E-mail: sandrysri@stanford.edu Received: October 27, 2020 Accepted: January 15, 2021 Published: February 10, 2021
